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Abstract
Introduction: Many people with rheumatoid arthritis (RA) do not receive care from a rheumatologist. We surveyed
primary care physicians (PCPs) to better understand their attitudes, knowledge, and practices regarding the optimal
treatment of RA.
Methods: Randomly selected PCPs practicing in the US were surveyed. The survey encompassed their experience
with RA, use of disease modifying anti-rheumatic drugs (DMARDs), and experience with rheumatology referrals.
Logistic regression analyses described the responses and examined the correlation between physician variables and
use of DMARDs.
Results: E-mail invitations were opened by 1, 103 PCPs and completed by 267 (25%). Most respondents were men
(68%) in practice for over 10 years (64%) who reported 6 or more RA patients under their care in the last year
(71%). The majority reported some RA training after medical school (59%), but only one-third felt very confident
managing this condition. Most (81%) reported prescribing DMARDs, but 37% do not initiate them, with only 9%
reporting being very confident starting a DMARD. In unadjusted analyses, several respondent characteristics were
strongly associated with not prescribing DMARDs, but none was significant after adjustment. Almost half (44%) of
PCPs noted that patients report difficulty getting appointments with rheumatologists.
Conclusions: We found many PCPs are uncomfortable managing RA with DMARDs, despite common beliefs that
their patients lack access to a rheumatologist. Lack of accessibility to rheumatologists and discomfort in prescribing
DMARDs for patients with RA are potential barriers to optimal treatment.
Introduction
Rheumatoid arthritis (RA) is the most common type of
systemic inflammatory arthritis and causes substantial
pain and disability [1]. The standard of care for RA has
been well established by all professional organizations of
rheumatology and includes the early initiation of dis-
ease-modifying anti-rheumatic drugs (DMARDs) [2,3].
Strong evidence supports such recommendations; early
DMARD use demonstrated better long-term functional
outcomes [4]. However, multiple studies from various
settings show that many patients with RA do not use
these drugs [5-8].
The strongest correlate of DMARD use across multi-
ple studies is the involvement of a rheumatologist in the
care of patients with RA [5,7]. Investigators have esti-
mated that patients who see a rheumatologist are four
to five times more likely to receive a DMARD than
those who receive care from an internist or family prac-
titioner [5,6]. Furthermore, at least two studies found a
more favorable outcome for patients treated regularly by
rheumatologists [9,10]. However, many patients with RA
do not see rheumatologists.
Many factors play a role in the management of RA,
but primary care physicians (PCPs) may play the biggest
role since they are often the first and only point of con-
tact for the patient. Thus, it is primarily up to the PCPs
to use their own clinical knowledge to determine the
‘course of action’ to meet each patient’s needs [11]. Stu-
dies on the management of RA have shown that, despite
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not to refer patients with RA to a rheumatic disease
expert; furthermore, it is rare for PCPs to initiate
DMARD therapy [12,13]. Moreover, even when PCPs
refer patients with RA to rheumatologists, there are too
few rheumatologists to adequately care for the growing
population in need of rheumatic disease expertise [9,14].
The shortage of rheumatologists manifests as long wait
times for rheumatology visits or lack of rheumatology
referral altogether or both [13]. Despite this evidence of
a rheumatologist shortage, relatively little is known
about PCPs’ interactions with patients with RA [14].
Therefore, it is important to explore the factors that are
related to PCPs’ management of RA and that may pre-
sent barriers to recommended RA care. Our aim was to
study PCPs’ attitudes, knowledge, and practices regard-
ing optimal treatment of RA, including DMARD use
and rheumatology referral.
Materials and methods
Survey participants
Participant recruitment was achieved through collabora-
tion with a survey vendor that has access to the Ameri-
can Medical Association physician directory. Through
this vendor, we sent e-mails to 5, 331 randomly selected
physicians who had e-mail addresses in the American
Medical Association physician directory and who had
self-designated as ‘family medicine’, ‘general practice’,o r
‘internal medicine’ providers. Each physician was sent
the e-mail on two occasions approximately 1 month
apart. The e-mail invitation included a link to the web-
based survey. A $75 honorarium gift card was offered
for completion of the survey. The study protocol and
survey were approved by the institutional review board
of Partners’ Healthcare. Informed consent was implied
by PCPs’ completion of the survey.
Survey
The survey consisted of sociodemographic information
as well as RA-specific items. The RA-specific items
focused on the respondents’ experience with RA as well
as their attitudes and knowledge of RA, DMARDs, and
rheumatology referrals. Experience with RA was gauged
through the respondents’ years in practice and current
number of patients with RA. Other questions ascer-
tained physicians’ attitudes and level of confidence
toward referring patients with RA to rheumatologists,
diagnosing RA, and prescribing DMARDs to patients
with RA. Knowledge questions dealt with the appropri-
ateness of DMARDs in RA as well as with RA training
that respondents may have received beyond medical
school. The survey ended with an open-ended item ask-
ing subjects whether they had any ideas for improving
care for patients with RA.
Statistical analysis
The statistical analyses described the survey responses
by calculating means and frequencies. We stratified sur-
vey responses according to whether respondents
reported DMARD prescribing or not. Also, survey
responses were stratified on the basis of the likelihood
of referral to rheumatologists. Correlates of DMARD
prescribing were examined in logistic regression models
that calculated the odds ratio for prescribing and 95%
confidence intervals. We assessed the odds ratios for all
variables and then advanced selected variables with P
values of less than 0.10 to a multivariable logistic regres-
sion model. All analyses were conducted with SAS 9.1
(SAS Institute Inc., Cary, NC, USA).
Results
Invitations were sent by e-mail to 5, 331 physicians; 1,
103 (20.7%) opened the e-mail and 756 opened the sur-
vey. Of those who opened the survey, 275 (36%) started
the survey and 272 completed the survey. Five were
removed from our analysis because we discovered, from
their answer to an open-ended question regarding RA
education beyond medical school, that they had training
in rheumatology. Our total sample consisted of 267 sub-
jects (Figure 1).
Characteristics of our sample are shown in Table 1.
The majority of our sample reported being in medical
practice for more than 10 years. The sample consisted of
physicians representing all regions of the US. Almost two
thirds of the physicians in our sample see 10 or fewer
patients with RA per year. The majority of our sample
stated that they were ‘somewhat confident’ in their ability
to diagnose RA, and approximately one third described
themselves as ‘very confident’.O v e rh a l fo ft h es a m p l e
stated that they had received additional RA education
beyond medical school; ‘journals or textbooks’ (39%) fol-
lowed by ‘residency’ (37%) were the most cited educa-
tional sources. Other popular sources of RA education
included ‘grand rounds’, ‘other continuing medical edu-
cation’, and ‘online continuing medical education’.
We explored DMARD prescribing patterns in the sur-
vey (Table 2). Approximately one fifth of subjects stated
that they did not prescribe DMARDs. Of the 217 who
reported prescribing DMARDs, 45% stated that they had
only continued a prescription (initially written by
another physician), 9% stated that they had only
initiated DMARDs, and the remainder reported writing
first prescriptions and continued prescriptions. The
most frequently prescribed DMARDs were non-biologics
such as methotrexate, hydroxychloroquine, and sulfasa-
lazine. However, 44% of prescribers reported prescribing
biologic DMARDs.
When asked what the best time to initiate DMARD
therapy was, a little over one half of subjects chose
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Page 2 of 8‘within the first 6 months of diagnosis’, whereas 35%
chose ‘after a trial of NSAIDs [non-steroidal anti-inflam-
matory drugs] or steroids’,a n d5 %c h o s e‘at least 6
months after diagnosis’. Less than 10% of subjects
reported being very comfortable initiating DMARDs.
The majority (61%) of subjects stated that they were
‘somewhat uncomfortable’ or ‘very uncomfortable’ start-
ing a DMARD; however, almost half (49%) stated that
they were ‘somewhat comfortable’ continuing DMARD
therapy. Common reasons cited for discomfort using
DMARDs included ‘toxicities’, ‘infections’,a n d‘intrave-
nous therapy’.
To better understand physician correlates of reporting
not prescribing DMARDs, we examined the probabilities
of DMARD use in logistic regression models (Table 3).
In unadjusted analyses, we found several strong corre-
lates of not prescribing DMARDs, such as fewer years in
practice, fewer patients with RA, lower confidence diag-
nosing RA, belief that less than half of patients with RA
are good candidates for DMARDs, and lacking sufficient
knowledge of DMARDs. However, none of these vari-
ables was statistically significant in adjusted analyses.
The majority (71%) of our sample stated that they
were very likely to refer patients with RA to a specialist
(Table 4). When the question ‘Under what situations
would you refer your patients to a rheumatologist?’ was
asked, ‘advanced disease’ was the most cited reason, fol-
lowed by ‘patient desire’ and ‘uncomfortable prescribing
DMARDs’.H o w e v e r ,a p p r o x i m a t e l yo n eq u a r t e r
reported that patients had difficulty getting appoint-
ments with rheumatologists. All of the physicians who
were unlikely to refer gave ‘no need’ as their reason for
not referring. However, they stated that they would refer
if the patient desired. Some answers respondents gave
when asked to describe ‘other’ reasons for referring their
patients to rheumatologists included ‘if they have insur-
ance’, ‘for biologics or for medications requiring intrave-
nous infusion’, ‘if not responding to DMARDs or failing
NSAIDs’,a n d‘compliance’. Some of the main reasons
the PCPs in our sample did not refer included ‘insur-
ance problems’, ‘too difficult to get a rheumatology
appointment’,a n d‘no need’. Seven percent of the total
sample stated their reason for not referring as ‘do not
know a practicing rheumatologist’.
Discussion
We studied the prescribing and referring habits of a
national sample of PCPs who took part in an e-mailed
Total Invitations, n= 5,331
Opened emails, n  = 1,103
Opened link to survey, n = 756
Completed survey, n = 272
Did not open, n= 4,228
Did not open link, n =347
Started survey, n = 275
Did not start survey, n = 481
Study Cohort Assembly
Incomplete Surveys, n =3
Rheumatologists (removed), n =5
Total Sample=267
Excludes
Figure 1 describes the assembly of the cohort.
Garneau et al. Arthritis Research & Therapy 2011, 13:R189
http://arthritis-research.com/content/13/6/R189
Page 3 of 8survey. Most of our subjects had more than 10 years of
practice and saw six or more patients with RA in the
last year. Nearly all subjects felt either somewhat confi-
dent or very confident in their ability to diagnose RA,
and most had received additional RA education beyond
medical school. Approximately one fifth of respondents
reported not prescribing DMARDs, and although 46% of
those who did claim to prescribe DMARDs stated that
they would both initiate and continue DMARD therapy,
45% stated that they would only continue DMARD ther-
apy and 9% stated they would only initiate DMARDs. Of
the 81% of our sample who reported prescribing a
DMARD, just over half stated that they were either
‘somewhat’ or ‘very’ uncomfortable starting a DMARD.
Most of our sample stated that they would refer their
patients with RA to rheumatologists, but 44% noted that
patients report difficulty getting appointments with a
rheumatologist.
These results suggest that PCPs commonly continue
DMARDs but that a minority initiate them. A high level
of discomfort prescribing DMARDs with difficulty
accessing rheumatology referrals may underpin reports
of suboptimal prescribing of DMARDs. There is also
evidence of early use of DMARDs; however, 40% of
those PCPs who prescribe DMARDs report that delayed
initiation is appropriate (Table 2). This ‘wait and see’
approach implies a lack of urgency toward aggressive
treatment and may contribute to the ‘no need’ attitude,
felt by some, for referral to a rheumatologist (Table 4).
Furthermore, when asked what factors make patients
inappropriate candidates for DMARD therapy, approxi-
mately half of the total respondents reported that there
was no need for a DMARD, one third noted patients
w e r et o os i c kt og e taD M A R D ,a n dm o r et h a nh a l ff e l t
that side effects of DMARDs were too problematic
(Table 2). Other concerns raised were drug interactions
and the cost of medications and their monitoring. We
asked our sample to give ideas for improving patient care
in regard to RA. The most popular idea was further train-
ing and education to improve comfort level diagnosing
RA and prescribing treatment. Much of our sample saw a
need for more continuing medical education, and several
requested a treatment algorithm to follow. Another fre-
quently cited idea by respondents for improving RA care
was increased access to rheumatologists for consultation
and patient appointments as well as more patient educa-
tion regarding RA and DMARD therapy.
The literature exploring PCPs’ referring and prescrib-
ing habits in regard to RA management is limited. One
study in Ontario, Canada, conducted a survey using a
case scenario to examine PCPs’ management of RA and
found that most physicians would diagnose RA properly;
however, rates of referral to specialists tended to be low
[13]. Another Canadian study surveyed family physicians
in Quebec and found that the vast majority of physi-
cians would make proper RA diagnoses in a vignette
c a s ea n dt h a ta b o u tt h r e ef o u r t h ss a i dt h a tt h e yw o u l d
refer patients to a rheumatic disease specialist; however,
only 4% mentioned initiating DMARD therapy [12].
Our findings were similar tot h o s eo ft h ea f o r e m e n -
tioned studies in regard to the ability and confidence of
PCPs to make a proper diagnosis; however, the Ontario
study showed that rates of referral were low whereas our
sample’s rate of referral was high. The Quebec study, like
ours, showed that the majority of PCPs would refer
patients with RA to specialists; however, only 4% men-
tioned initiating DMARD therapy whereas 80% of our
sample stated that they would prescribe DMARDs. Our
study is more recent, and this may explain the different
attitudes of PCPs to the use of DMARDs. Additionally,
Table 1 Characteristics of survey respondents (n = 267)
Number
(percentage)
Female gender
a 86 (32%)
Years practicing medicine
0-1 4 (1%)
2-5 43 (16%)
6-10 50 (19%)
11-15 40 (15%)
16+ 130 (49%)
Region of practice
West 125 (47%)
Midwest 41 (15%)
Northeast 14 (5%)
South 86 (32%)
RA patients seen in last year
0-5 77 (29%)
6-10 91 (34%)
11+ 99 (37%)
Confidence in ability to diagnose RA
Very confident 83 (31%)
Somewhat confident 161 (61%)
Less than confident 19 (7%)
No confidence 3 (1%)
Additional RA education beyond medical
school
Yes 156 (59%)
Source of training regarding RA
Residency 100 (37%)
Fellowship 4 (2%)
Grand rounds 59 (22%)
Online continuing medical education 54 (20%)
Other continuing medical education 59 (22%)
Journals or textbooks or both 104 (39%)
Other conferences 48 (18%)
Other 3 (1%)
aSix missing. RA, rheumatoid arthritis.
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health-care systems. One additional difference that may be
important to note between our study and these Canadian
studies is the difference in response rates. Whereas studies
by Bernatsky and colleagues [12] and Glazier and collea-
gues [13] yielded response rates of 31% and 68%, respec-
tively, our study produced a response rate of only 25%.
Possible reasons for this difference might be that the two
Table 2 Information on prescribing disease-modifying anti-rheumatic drugs
Total DMARD prescribers
a DMARD non-prescribers
n = 266
b n = 217 n =4 9
Initial prescription, continuation, or both
First only 20 (9%)
Continuation only 98 (45%)
Both 99 (46%)
Prescribed DMARDs
Methotrexate 195 (90%)
Hydroxychloroquine 171 (79%)
Sulfasalazine 135 (62%)
Leflunomide 43 (20%)
Gold 35 (16%)
Azathioprine 54 (25%)
Cyclosporine 32 (15%)
Abatacept 8 (4%)
Etanercept 64 (29%)
Infliximab 56 (26%)
Rituximab 20 (9%)
Adalimumab 43 (20%)
Certolizumab pegol 2 (1%)
Golimumab 1 (0%)
Type of DMARDs prescribed
a
Biologic and non-biologic DMARDs 96 (44%)
Non-biologic DMARDs only 118 (54%)
Biologic DMARDs only 2 (1%)
Factors that make patients inappropriate candidates for DMARDs
No need (well controlled without DMARDs) 131 (49%) 110 (51%) 21 (43%)
Too sick to take a DMARD 92 (35%) 78 (36%) 14 (29%)
Side effects of DMARDs too problematic 148 (56%) 128 (59%) 20 (41%)
Drug interactions 83 (31%) 74 (34%) 9 (18%)
Drug cost and monitoring are too high 142 (55%) 115 (53%) 27 (55%)
Cannot get laboratory monitoring 20 (8%) 17 (8%) 3 (6%)
Best time to initiate DMARDs
After a trial of NSAIDs or steroids 92 (35%) 75 (35%) 17 (35%)
Within the first 6 months of diagnosis 159 (60%) 132 (61%) 27 (55%)
At least 6 months after diagnosis 13 (5%) 9 (4%) 4 (8%)
Comfort level starting a DMARD
c
Very comfortable 23 (9%) 23 (11%) 0 (0%)
Somewhat comfortable 79 (30%) 73 (34%) 6 (12%)
Somewhat uncomfortable 112 (42%) 89 (41%) 23 (47%)
Very uncomfortable 50 (19%) 30 (14%) 20 (41%)
Comfort level continuing a DMARD
d
Very comfortable 75 (28%) 71 (33%) 4 (8%)
Somewhat comfortable 130 (49%) 107 (50%) 23 (47%)
Somewhat uncomfortable 54 (20%) 37 (17%) 17 (35%)
Very uncomfortable 6 (2%) 1 (0%) 5 (10%)
aOne prescriber did not fill in types of disease-modifying anti-rheumatic drugs (DMARDs).
bOne missing response.
cThree missing responses.
dTwo missing
responses. NSAID, non-steroidal anti-inflammatory drug.
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whereas our surveys were internet-based and that the
Canadian studies repeated their mailings at least two times
whereas we did only one follow-up mailing. Additionally,
we do not know what type of incentive the Canadian
researchers offered their respondents for completing the
survey and therefore these studies cannot be compared
with ours.
Several limitations of this research are important to
note. There are several issues regarding generalizability
Table 3 Probability of not prescribing a disease-modifying anti-rheumatic drug
Univariate,
OR (95% CI)
Multivariate
a,
OR (95% CI)
Years practicing medicine
0-1 5.07 (0.69-37) 1.44 (0.14-14.83)
2-10 1.30 (0.68-2.49) 0.98 (0.48-2.01)
11+ 11
RA patients seen in last year
0-5 2.46 (1.30-4.67) 1.74 (0.85-3.58)
6+ 11
Confidence in ability to diagnose RA
Very of somewhat confident 1 1
Less than or no confidence 3.53 (1.41-8.82) 2.07 (0.72-5.95)
Additional RA education beyond medical school
Yes 11
No 1.46 (0.79-2.73) 0.92 (0.45-1.89)
Proportion of RA patients who are good candidates for DMARDs
0%-50% 2.88 (1.22-6.82) 2.41 (0.96-6.08)
51%-75% 1.01 (0.39-2.59) 0.85 (0.31-2.32)
76%-100% 11
Physicians’ knowledge level of DMARDs
Very knowledgeable 1 1
Somewhat knowledgeable 2.13 (0.27-16) 1.22 (0.15-10.2)
Lacking sufficient or any knowledge 9.87 (1.23-79) 5.20 (0.60-44)
aMultivariate model included all variables shown in the table. CI, confidence interval; DMARD, disease-modifying anti-rheumatic drug; OR, odds ratio; RA,
rheumatoid arthritis.
Table 4 Factors influencing referral to rheumatologist for rheumatoid arthritis
Likelihood of referring
Total cohort Very likely Possible Unlikely
(n = 266
a)( n = 189) (n = 73) (n =4 )
Situations leading up to referral
Advanced disease 213 (80%) 153 (81%) 60 (82%) 0 (0%)
Patient desire for a referral 211 (79%) 153 (81%) 54 (74%) 4 (100%)
Uncomfortable prescribing DMARDs 186 (70%) 152 (80%) 33 (45%) 1 (25%)
Patient comorbidities 107 (40%) 85 (45%) 20 (27%) 2 (50%)
Other 14 (5%) 11 (6%) 3 (4%) 0 (0%)
Patients report of difficulty getting rheumatology appointment
b
Yes, most of the time 74 (44%) 49 (40%) 25 (57%) 0 (0%)
No, never 95 (56%) 74 (60%) 19 (43%) 2 (50%)
Main reason for not referring
Do not know a rheumatologist 19 (7%) 10 (5%) 9 (12%) 0 (0%)
Rheumatology appointment too difficult to get 73 (27%) 46 (24%) 27 (37%) 0 (0%)
No need 63 (24%) 32 (17%) 27 (37%) 4 (100%)
Insurance problems 107 (40%) 74 (39%) 33 (45%) 0 (0%)
Other 48 (18%) 37 (20%) 11 (15%) 0 (0%)
aOne missing response.
bOne hundred three missing responses because of an error in the electronic survey. DMARD, disease-modifying anti-rheumatic drug.
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respondents who answer internet-based surveys are
those who are keyboard and internet literate - currently
only a third of the adult population in the US. Second,
internet based surveys frequently confuse respondents in
their instructions. A third problem noted was a lack of
time, leading to some respondents’ preference to take
the survey in locations other than online. It was sug-
gested that respondents may then choose to print out
t h es u r v e ya n dt a k ei ti na n o t h e rl o c a t i o n ,a n dt h i s
would potentially exclude these respondents’ answers,
creating a bias [15]. There was also a relatively low
response rate. Of those who opened the e-mail, 25%
completed the survey. This response rate, while lower
than one might hope, is similar to that of other e-mailed
surveys [16]. Additionally, literature supporting the relia-
bility of internet questionnaires as a surveying tool exists
[17]. Our survey was not a validated questionnaire but a
compilation of questions that regarded attitudes toward
and knowledge about RA and that deserved further
attention. Finally, we were unable to determine whether
respondents were representative of the entire sample
with regard to demographics.
Conclusions
We surveyed a US sample of PCPs in regard to the
management of RA. We found that many PCPs are
uncomfortable managing RA with DMARDs, despite
common beliefs that their patients lack access to a rheu-
matologist. Lack of accessibility to rheumatologists and
discomfort in prescribing DMARDs for patients with
RA are potential barriers to optimal treatment. Future
directions for research into improving RA care may
include the design of educational programs for PCPs to
gain greater comfort prescribing DMARDs. It might also
be prudent to develop ways in which rheumatic disease
specialists can work more closely with PCPs to treat RA
by using a ‘team’ approach. Such models have been
developed for diabetes and depression [18,19]. Other
options for improving treatment would be to further
involve non-physician providers, such as nurse practi-
tioners or physician assistants, in managing DMARDs. If
such approaches are found to be effective, RA manage-
ment may be improved substantially.
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